GVHD
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Neovii BiotechUS-ATG-F
REGiMMUNEFLUDARABINE
Clinical Trials (2)
Total enrollment: 285 patients across 2 trials
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Start: Oct 2011Est. completion: Oct 2015260 patients
Phase 3Completed
Haplo Peripheral Blood Sct In GVHD Prevention
Start: Aug 2020Est. completion: Aug 202425 patients
Phase 1Completed
Related Jobs
Associate, Cell Therapy Production, 1st Shift
Sacramento, CA
6d ago
$23 - $28/yr
Material Planner
Sacramento, CA
3w ago
$75K - $105K/yr
Manager, Warehouse
Sacramento, CA
3w ago
$100K - $145K/yr
Manager / Senior Manager, Business Systems
Sacramento, CA; Menlo Park, CA
3w ago
$140K - $180K/yr
Medical Director / Senior Medical Director, Clinical Development
Menlo Park, CA
3w ago
$225K - $325K/yr
Sr. Scientist/Principal Scientist, CMC Analytical Development
Sacramento, CA
3w ago
$140K - $170K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.